Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus
The protein has a calculated MW of 81.9 kDa. The protein migrates as 110-125 kDa under reducing (R) condition, and 200- 240 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus M-CSF R, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Biotinylated Human M-CSF, His,Avitag (Cat. No. MCF-H82E6) at 2 μg/mL (100 μL/well) on streptavidin precoated (0.2 μg/well) plate, can bind Cynomolgus M-CSF R, Fc Tag (Cat. No. CSR-C5252) with a linear range of 1-39 ng/mL (QC tested).
Immobilized Human M-CSF, His Tag (Cat. No. MCF-H5247) at 5 μg/mL (100 μL/well) can bind Cynomolgus M-CSF R, Fc Tag (Cat. No. CSR-C5252) with a linear range of 1-39 ng/mL (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors | Details |
pacritinib citrate | SB-1518; ONX-0803 | Approved | S*BIO Pte Ltd, Concert | VONJO | United States | Primary Myelofibrosis | Sobi | 2022-02-28 | Lymphoproliferative Disorders; Sarcoma, Kaposi; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocythemia, Essential; Carcinoma, Non-Small-Cell Lung; Inflammation; Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Thrombocytopenia; Leukemia, Myelomonocytic, Juvenile; Hepatic Insufficiency; Castleman Disease; Leukemia, Myelogenous, Chronic; Colorectal Neoplasms; Primary Myelofibrosis; X-Linked Combined Immunodeficiency Diseases; Lymphoma, Mantle-Cell; Coronavirus Infections; Hodgkin Disease; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Polycythemia Vera; Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Leukemia | Details |
Surufatinib | HMPL-012 | Approved | Hutchison Medipharma Ltd | 苏泰达, SULANDA | Mainland China | Neuroendocrine Tumors | Hutchison Medipharma Ltd | 2020-12-29 | Biliary Tract Neoplasms; Solid tumours; Intestinal Neoplasms; Hematologic Neoplasms; Renal Insufficiency; Neoplasms; Pancreatic neuroendocrine tumors (pNET); Small Cell Lung Carcinoma; Pancreatic Neoplasms; Neuroendocrine Tumors; Sarcoma; Hepatic Insufficiency; Bile Duct Neoplasms; Appendiceal Neoplasms; Thyroid Neoplasms; Carcinoma, Neuroendocrine | Details |
Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Kidney Neoplasms; Skin Melanoma; Teratoma; Liver Neoplasms; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Lymphoma, B-Cell; HIV Infections; Fibrosarcoma; Intestinal Neoplasms; Fibromatosis, Aggressive; Leukemia; Lymphoma, B-Cell, Marginal Zone; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Abdominal Neoplasms; Pelvic Neoplasms; Polycythemia Vera; Thoracic Neoplasms; Esophageal Neoplasms; Carcinoma, Islet Cell; Carcinoma; Histiocytoma, Malignant Fibrous; Hemangioblastoma; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Nose Neoplasms; Hypopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic neuroendocrine tumors (pNET); Plasmacytoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Myelodysplastic Syndromes; Carcinoma, Transitional Cell | Details |
Axatilimab | SNDX-6352; UCB-6352; INCA-34176; INCA034176; INCA-034176 | Approved | Ucb | NIKTIMVO | United States | Graft vs Host Disease | Incyte Corp | 2024-08-14 | Myeloproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases; Neoplasm Metastasis; Coronavirus Infections; Cholangiocarcinoma; Breast Neoplasms; Respiratory Distress Syndrome, Adult; Neoplasms; Leukemia, Myelomonocytic, Chronic; Solid tumours; Hodgkin Disease; Idiopathic Pulmonary Fibrosis; Triple Negative Breast Neoplasms; Graft vs Host Disease; Leukemia, Myelogenous, Chronic; Bone Marrow Neoplasms; Cytokine Release Syndrome | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Metastatic breast cancer; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Neurofibroma, Plexiform; Neurofibrosarcoma; Giant Cell Tumors; Sarcoma; Giant Cell Tumor of Tendon Sheath; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pancreatic Neoplasms; Neoplasms; Arthritis, Rheumatoid; Hodgkin Disease; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Synovitis, Pigmented Villonodular; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Solid tumours | Details |
Mirimostim | P-100; CSF-HU | Approved | Jcr Pharmaceuticals Co Ltd | Costilate, Leukoprol | Japan | Neutropenia | Jcr Pharmaceuticals Co Ltd | 1991-01-01 | Neutropenia | Details |
Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Osteosarcoma; Germinoma; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Uterine Cervical Diseases; Genital Neoplasms, Female; Gliosarcoma; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Chondrosarcoma, Extraskeletal Myxoid; Lung Neoplasms; Nasopharyngeal Carcinoma; Medullary thyroid cancer (MTC); Brain Neoplasms; Urethral Neoplasms; Psoriasis; Gastrinoma; Neuroblastoma; Prostatic Neoplasms; Breast Neoplasms; Neoplasms, Germ Cell and Embryonal; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Neoplasm Metastasis; Breast Neoplasms, Male; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Paraganglioma; Melanoma; Macular Degeneration; Carcinoma, Hepatocellular; Sarcoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Choriocarcinoma; Uterine Neoplasms; Lymphoma; Carcinoma, Neuroendocrine; Glioma; Carcinoma, Embryonal; Skin Melanoma; Neoplasms; Herpes Genitalis; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Insulinoma; Pheochromo | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Simmitinib hydrochloride | SOMCL-15-290 | Phase 3 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
Seralutinib | GB-002; PK-10571 | Phase 3 Clinical | Gilead Sciences Inc | Pulmonary Arterial Hypertension | Details |
Chiauranib | CS-2164; CS2164 | Phase 3 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Carcinoma, Hepatocellular | Details |
Pimicotinib | ABSK-021 | Phase 3 Clinical | ABbisko Therapeutics Co Ltd | Giant Cell Tumor of Tendon Sheath; Solid tumours; Synovitis, Pigmented Villonodular; Neoplasms; Graft vs Host Disease; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Sarcoma; Lung Neoplasms; Amyotrophic Lateral Sclerosis | Details |
Emactuzumab | RG-7155; 6FY6EI1X8R; RO-5509554 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Head and Neck Neoplasms; Solid tumours; Carcinoma; Neoplasms; Prostatic Neoplasms; Testicular Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin | Details |
Recombinant human GM-CSF oncolytic herpes simplex virus type 2 (OH2) | BS-001; BS001; oHSV-2; OH-2; OH2; OH2 injection; oHSV2hGM-CSF | Phase 3 Clinical | Wuhan Binhui Biotechnology Co Ltd | Central Nervous System Neoplasms; Melanoma; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Sarcoma; Breast Neoplasms; Digestive System Neoplasms; Liver Neoplasms; Liver Diseases; Urinary Bladder Neoplasms; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Esophageal Neoplasms; Solid tumours; Head and Neck Neoplasms | Details |
Tinengotinib | TT-00420; TT 00420; TT00420 | Phase 3 Clinical | TransThera Sciences (Nanjing) Inc | Biliary Tract Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Cholangiocarcinoma; Sarcoma; Prostatic Neoplasms; Gallbladder Neoplasms; Thyroid Neoplasms | Details |
LY-3022855 | IMC-CS4; LY-3022855 | Phase 2 Clinical | Eli Lilly And Company | Solid tumours; Neoplasms; Pancreatic Neoplasms; Melanoma; Neoplasm Metastasis | Details |
Cabiralizumab | FPA-008; ONO-4687; BMS-986227 | Phase 2 Clinical | Five Prime Therapeutics Inc | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Giant Cell Tumor of Tendon Sheath; Lymphoma, T-Cell, Peripheral; Carcinoma, Renal Cell; Synovitis, Pigmented Villonodular; Neoplasms; Triple Negative Breast Neoplasms; Arthritis, Rheumatoid; Pancreatic Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
Narazaciclib | ON-123300; HX-301 | Phase 2 Clinical | Temple University | Solid tumours; Glioblastoma; Multiple Myeloma; Breast Neoplasms; Glioma; Endometrial Neoplasms | Details |
Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
HH185 | 3D-185; 3-D185; HH-185; 3D185 | Phase 2 Clinical | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc | Solid tumours; Cholangiocarcinoma | Details |
C-019199 | C019199 | Phase 2 Clinical | Fujian Haixi Pharmaceuticals Co Ltd | Giant Cell Tumor of Tendon Sheath; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Osteosarcoma; Breast Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma | Details |
Elzovantinib | TPX-0022 | Phase 2 Clinical | Turning Point Therapeutics Inc | Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
AMB-066 | AMB-066 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center, AmMax Bio Inc | Colorectal Neoplasms | Details |
BS-008 | BS001/BS006; BS001+BS006 | Phase 2 Clinical | Wuhan Binhui Biotechnology Co Ltd | Solid tumours; Sarcoma; Colorectal Neoplasms | Details |
Enrupatinib | EI-1071; FB-1071 | Phase 2 Clinical | Elixiron Immunotherapeutics Inc | Giant Cell Tumor of Tendon Sheath; Alzheimer Disease; Nervous System Diseases; Amyotrophic Lateral Sclerosis | Details |
[11C]CPPC | Phase 2 Clinical | Johns Hopkins University | Post-Acute COVID-19 Syndrome; Amyotrophic Lateral Sclerosis | Details | |
AMB-051 | AMB 053; AMB-055; AMG-820; AMB-051; AMB-05X | Phase 2 Clinical | Amgen Inc | Giant Cell Tumor of Tendon Sheath; Solid tumours; Synovitis, Pigmented Villonodular; Idiopathic Pulmonary Fibrosis; Neoplasms; Pancreatic Neoplasms; Testicular Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Adrixetinib | Q-702 | Phase 2 Clinical | Vichem Chemie, Max Planck Institute of Biochemistry, Lead Discovery Center GmbH | Lymphoma, Follicular; Central Nervous System Lymphoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Primary Myelofibrosis; Histiocytic Sarcoma; Erdheim-Chester Disease; Hematologic Neoplasms; Histiocytosis, Langerhans-Cell; Histiocytosis, Sinus; Neoplasms; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Stomach Neoplasms; Esophageal Neoplasms; Leukemia, Lymphoid; Solid tumours; Lymphoma, T-Cell, Peripheral | Details |
SYHA-1813 | SYHA1813 | Phase 2 Clinical | Shanghai Runshi Pharmaceutical Technology Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours; Giant Cell Tumor of Tendon Sheath; Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Gliosarcoma; Lung Neoplasms; Brain metastases; Glioma; Thyroid Neoplasms; Meningioma | Details |
PMI-04 | Phase 1 Clinical | Precision Molecular Inc | Nerve Degeneration | Details | |
APL-102 | APL-102; CBT-102 | Phase 1 Clinical | Apollomics Inc | Solid tumours | Details |
Edicotinib | PRV-6527; JNJ-244; JNJ-40346527-AAC-G-002; JNJ-40346527; JNJ-527 | Phase 1 Clinical | Johnson & Johnson | Hodgkin Disease; Arthritis, Rheumatoid; Prostatic Neoplasms; Alzheimer Disease; Cognitive Dysfunction; Leukemia, Myeloid, Acute; Crohn Disease | Details |
Pamufetinib | TAS-115 | Phase 1 Clinical | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | Neoplasms | Details |
JDB-383 | JDB-383 | Phase 1 Clinical | Shanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd | Giant Cell Tumor of Tendon Sheath | Details |
HMPL-653 | HMPL-653 | Phase 1 Clinical | Hutchison Medipharma Ltd | Solid tumours; Giant Cell Tumor of Tendon Sheath; Testicular Neoplasms | Details |
MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis | Details |
ETH-155036 | ETH-155036; ETH155036 | Phase 1 Clinical | Shengke Pharmaceutical (Jiangsu) Co Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Caflanone | FBL-03G | Phase 1 Clinical | Flavocure Biotech Inc | Pancreatic Neoplasms | Details |
SYHA-1817 | SYHA-1817 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell | Details |
TT-00420/Atezolizumab | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Gastrointestinal Neoplasms | Details | |
BC-006 | BC-006; BC006; ADG125; ADG-125 | Phase 1 Clinical | Adagene Inc | Giant Cell Tumor of Tendon Sheath; Solid tumours | Details |
AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.